BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

69.25
EUR
-1.29
(-1.83%)
-2.61EPS
11.45BMarket Cap
Feb 25Next Earn

BridgeBio Pharma, Inc. Documents

Q3 FY2025 · Press release

BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1-2025 (1) · October 29, 2025 · 5 pages

Read BridgeBio Pharma, Inc.'s results firsthand

Preview the first 2 pages of this press release
Create a free account to start reading

Full documents are included with Professional

Q3 FY2025 documents